Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) dropped 5% during mid-day trading on Wednesday . The stock traded as low as $32.38 and last traded at $32.54. Approximately 46,321 shares were traded during trading, a decline of 90% from the average daily volume of 453,536 shares. The stock had previously closed at $34.25.
Analysts Set New Price Targets
SYRE has been the topic of several research analyst reports. Wells Fargo & Company raised shares of Spyre Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $12.00 to $35.00 in a research note on Friday, March 1st. Stifel Nicolaus upped their price objective on shares of Spyre Therapeutics from $36.00 to $54.00 and gave the stock a “buy” rating in a report on Tuesday, March 26th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $39.20.
Get Our Latest Analysis on SYRE
Spyre Therapeutics Stock Up 3.4 %
Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last released its quarterly earnings results on Thursday, February 29th. The company reported ($2.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($1.80). As a group, research analysts anticipate that Spyre Therapeutics, Inc. will post -2.36 EPS for the current fiscal year.
About Spyre Therapeutics
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
See Also
- Five stocks we like better than Spyre Therapeutics
- What is an Earnings Surprise?
- 3 Stocks Leading the U.S. Agriculture Comeback
- Insider Buying Explained: What Investors Need to Know
- How to Use Put Debit Spreads to Profit From Falling Stocks
- How is Compound Interest Calculated?
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.